Pharmacological implications in the switch from acute to chronic inflammation

Inflammopharmacology

Volumn 10, Issue 3, 2002, Pages 159-171

  Dallegri, Franco ^a,b   Ottonello, Luciano ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Anti inflammatory drugs; Nuclear factor; Oxaprozin; Signal transduction; T lymphocytes

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE; ANTIINFLAMMATORY AGENT; CORTICOSTEROID; CYCLOSPORIN A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; LEFLUNOMIDE; OXAPROZIN; SALAZOSULFAPYRIDINE; TACROLIMUS; TUMOR NECROSIS FACTOR RECEPTOR;

APOPTOSIS; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC INFLAMMATION; CONCENTRATION RESPONSE; CONFERENCE PAPER; CYTOKINE PRODUCTION; DRUG INHIBITION; ENDOTHELIUM CELL; FIBROBLAST; IMMUNE RESPONSE; IMMUNOSTIMULATION; INFLAMMATION; INFLAMMATORY CELL; MACROPHAGE; MACROPHAGE ACTIVATION; MONOCYTE; PRIORITY JOURNAL; T LYMPHOCYTE; TH1 CELL;

EID: 0036948699     PISSN: 09254692     EISSN: None     Source Type: Journal    
DOI: 10.1163/156856002321168187     Document Type: Conference Paper

References (24)

1. Arend, W. P. (2001). Cytokine imbalance in the pathogenesis of rheumatoid arthritis: the role of interleukin-1 receptor antagonist. Sem. Arthritis Rheum. 30, 1-6.
2. Baracchini, A., Minisola, G., Amicosante, G., et al. (2001). Oxaprozin: a NSAID able to inhibit the matrix metallo-proteinase activity, Inflammopharmacology 9, 143-146.
3. Bevilacqua, M. (2000). Pharmacology of oxaprozin: novel findings, in: Oxaprozin and the daily management of osteomuscolar impairment in arthritic patients, Highlights from the Satellite Symposium on Oxaprozin at the XIV EULAR Congress, pp. 3-6. Adis International, Milan, Italy.
4. Bevilacqua, M. (2002). Oxaprozin, a derivative of 2-arylpropionic acid, inhibits nuclear factor-kb at therapeutically relevant concentrations, Ann. Rheum. Dis. 61. (Suppl. 1), p. 355, Abstract n. 18.
5. Choy, E. H. S. and Panayi, G. S. (2001). Cytokine pathways and joint inflammation in rheumatoid arthritis, New Engl. J. Med. 344, 907-916.
6. Coleman, J. W. (2001). Nitric oxide in immunity and inflammation, Int. Immunopharmacol. 1, 1397-1406.
7. Colville-Nash, P. R. and Gilroy, D. W. (2000). COX-2 and the cyclopentenone prostaglandins - a new chapter in the book of inflammation?, Prost. Lipid Mediators 62, 33-43.
8. Firestein, G. S. and Zvaifler, N. J. (2002). How important are T cells in chronic rheumatoid synovitis? Arthritis Rheum. 46, 298-308.
9. Gong J. H., Ratkay, L. G., Waterfield, D., et al. (1997). An antagonist of monocyte chemoattractant protein 1 (MCP-1) inhibits arthritis in the MRL-1pr mouse model, J. Exp. Med. 186, 131-137.
10. Israel, A. (2000). The IKK complex: an integrator of all signals that activate NF-kB, Trends Cell. Biol. 10, 129-133.
11. Kaiser, S. M. and Quinn, R. J. (1999). Adenosine receptors as potential therapeutic targets, Drug Discov. Today 4, 542-551.
12. Kinne, R. W., Brauer, R., Stuhlmuller, B., et al. (2000). Macrophages in rheumatoid arthritis, Arthritis Res. 2, 189-202.
13. Makarov, S. S. (2000). NF-κB as a therapeutic target in chronic inflammation: recent advances, Mol. Med. Today 6, 441-448.
14. McInnes, I. B. and Liew, F. Y. (1998). Interleukin 15: a proinflammatory role in rheumatoid arthritis synovitis, Immunol. Today 19, 75-79.
15. McInnes, I. B., Leung, B. P. and Liew, F. Y. (2000). Cell-cell interactions in synovitis. Interactions between T lymphocytes and synovial cells, Arthritis Res. 2, 374-378.
16. Mulherin, D., Fitzgerald, O. and Bresnihan, B. (1996). Synovial tissue macrophage populations and articular damage in rheumatoid arthritis, Arthritis Rheum. 39, 115-124.
17. Ottonello, L., Cutolo, M., Frumento, G., et al. (2002). Synovial fluid from patients with rheumatoid arthritis inhibits neutrophil apoptosis: role of adenosine and pro-inflammatory cytokines, Rheumatology (in press).
18. Pap, T., Muller-Ladner, U., Gay, R. E., et al. (2000). Role of synovial fibroblasts in the pathogenesis of rheumatoid arthritis, Arthritis Res. 2, 361-367.
19. Piomelli, D., Giuffrida, A., Calignano, A., et al. (2000). The cannabinoid system as a target for therapeutic drugs, Trends Pharmacol. Sci. 21, 218-224.
20. Ritchlin, C. (2000). Fibroblast biology. Effector signals released by synovial fibroblast in arthritis, Arthritis Res. 2, 356-360.
21. Tak, P. P. and Bresnihan, B. (2000). The pathogenesis and prevention of joint damage in rheumatoid arthritis, Arthritis Rheum. 43, 2619-2633.
22. Tak, P. P. and Firestein, G. S. (2001). NF-kB: a key role in inflammatory diseases, J. Clin. Invest. 107, 7-11.
23. Taylor, P. C., Williams, R. O. and Maini, R. N. (2001). Immunotherapy for rheumatoid arthritis, Curr. Opin. Immunol. 13, 611-616.
24. Yamamoto, Y. and Gaynor, R. B. (2001). Therapeutic potential of inhibition of NF-kB pathway in the treatment of inflammation and cancer, J. Clin. Invest. 107, 135-141.